Oncology

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, associate editor of Evidence-Based Oncology, and vice president of the Community Oncology Alliance, discusses his new book.

A recent survey showed the disruption in cancer care as a result of the pandemic is worrying professionals who provide psychosocial support to patients.

Proposed CMS rules would make it easier for state Medicaid programs to smooth the way for value-based contracts for high-cost gene therapies.

As the American Society of Clinical Oncology calls for more aggressive efforts to bring equity to cancer care, authors in JAMA Oncology say COVID-19 is creating wider gaps.

A new treatment option is approved for patients with a common form of non-Hodgkin lymphoma who cannot have an autologous stem cell transplant.

The American Oncology Network, LLC, has added 5 medical oncologists to its Executive Committee.

“We’ve had advancements, but we need to go faster,” said ASCO President Howard A. "Skip" Burris III, MD, as he stressed the importance of advancing therapies for better patient outcomes by addressing obstacles to patients’ care. “Access to care, access to clinical trials, and access to information are really key.”

Nathan H. Walcker will succeed Brad Prechtl on August 1, 2020.

Federal and state officials have implemented policies and safeguards to slow transmission of the virus. Most troubling were state moratoriums on “elective” surgical procedures.

As I recall the early days of the HIV/AIDS pandemic, what stands out most is its profound human cost and the courage of those who helped our society transcend it. We are in the midst of a time in which the human toll of COVID-19 and the enormity of the path ahead are clear.

Coverage from the Community Oncology Alliance Virtual Meeting, held April 23-24, 2020.

The American Society of Clinical Oncology recommends that cancer survivors who have completed their treatment and are under surveillance with no known evidence of disease are to be kept out of care facilities to avoid developing COVID-19.

Investigators reported in Lancet Oncology that second-line treatments are needed in small cell lung cancer, as few options exist for these patients once first-line therapy fails.

The authors established a claims-based mechanism for identifying patients with lung cancer with more severe patient-reported cancer-related symptoms who could benefit from engagement with health care programs.

Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

In each performance period of the Oncology Care Model for which we've received data, we've seen different aspects of care that we can improve upon in the following 6 months, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

The Oncology Care Model (OCM) has helped practices develop their capacity to use data for continuous quality improvement, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

There will never be all mandatory payment models or all value-based models, but we can craft a value-based model around just about anything as long as everybody agrees on what the criteria is, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.

New technologies and quick drug approvals contribute to the challenges of incorporating value-based care in oncology, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.

Raising awareness on the involvement of primary care providers can assist cancer survivors in transitioning from oncology care, said Kelly Filchner, MSN, director at Fox Chase Cancer Center Partners.

Transformational changes in cancer care can bring forth important innovations, but all those come at a cost, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The Supreme Court says insurers are owed $12 billion under the Affordable Care Act; a study finds those with cancer are at higher risk from coronavirus disease 2019 (COVID-19); a survey shows millions would avoid seeking care for COVID-19 due to cost.

Delays in reporting Oncology Care Model results from performance periods creates tremendous uncertainty, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.

Innovations to promote communication between primary care providers, oncologists are vital to delineate distinct roles in oncology patient management, said Kelly Filchner, MSN, director at Fox Chase Cancer Center Partners.

Despite the immediate distraction from coronavirus disease 2019 (COVID-19), panelists at the 2020 Virtual Community Oncology Conference said community oncologists must keep pressure on pharmacy benefit managers (PBMs) as the 2020 campaign heats up—lest they lose the momentum to rein PBM practices within the umbrella of drug pricing reform.

The bright spot of telemedicine's success during the coronavirus disease 2019 pandemic cannot overshadow the stresses on patients and practices, which will both have ongoing challenges when the pandemic ends, said panelists during a legislative update on day 2 of the 2020 Virtual Community Oncology Conference, convened by the Community Oncology Alliance.

This week, the top managed care news included HHS' plans to allocate the remaining $70 billion in COVID-19 funding to providers; an analysis finding aggressive social distancing measures economically justified; highlights from this week's virtual Community Oncology Conference.

Oncology practices in 2-sided risk arrangements have reported mixed results, pointing to the need for more time to make the transition, said Michael Diaz, MD, president of Community Oncology Alliance.

Many patients when they start their cancer therapy get so ingrained in the cancer world that their oncologist just becomes their main point of contact, but we have to do a better job at letting the patients know that the PCP still is an integral part of their care, said Kelly Filchner, MSN, director at Fox Chase Cancer Center Partners.